Psilocybin therapy for mood dysfunction in Parkinson’s disease: an open-label pilot trial

A small clinical trial suggests that low-dose psilocybin, a naturally occurring psychedelic compound, may offer meaningful relief from depression and anxiety for people living with Parkinson’s disease (PD). Early Findings Suggest More Than Mood Support The pilot Phase 2 study, conducted at the University of California San Francisco’s Translational Psychedelic Research (TrPR) program, also found signs that psilocybin may help with cognitive and motor symptoms—challenges that many people with Parkinson’s face over time. What the Study Involved Twelve adults with mild to moderate Parkinson’s, all experiencing depression and/or anxiety, took part in the trial. Each received two doses of psilocybin (10 mg, then 25 mg two weeks later), combined with professional psychotherapy. Sessions were held in a calm setting with trained therapists present to support safety and comfort. Improvements in Mood, Memory, and Movement Participants were followed for three months. Many reported: Reduced depression and anxiety Improved memory and learning Better motor function, including fewer difficulties with daily tasks These improvements were measured using well-established clinical scales. Most side effects, such as mild nausea or temporary anxiety, were manageable and did not require medical care. A New Direction in Parkinson’s Research Mood symptoms such as depression and anxiety often appear before motor issues in Parkinson’s and are closely linked to a person’s quality of life and rate of decline. The research team believes psilocybin’s potential lies in its ability to reduce inflammation and support brain plasticity—the brain’s ability to adapt and heal. “This is just the beginning,” said Dr. Ellen Bradley, the study’s lead author. “But it raises real hope for new ways to support people living with Parkinson’s.” What’s Next? A larger follow-up study is now underway, with support from The Michael J. Fox Foundation for Parkinson’s Research and an anonymous donor. This new trial will include about 100 participants and will look more closely at psilocybin’s effects on mood, movement, inflammation, and brain health.